|
|
|
|
|
|
|
|
|
11.03.26 - 21:21
|
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering (GlobeNewswire EN)
|
|
|
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced the closing of its previously announced registered direct offering of 4,500,785 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 4,500,785 shares of Common Stock at a combined offering price of $1.739 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant. The Accompanying Warrants have an exercise price of $1.614 per share of Common Stock, are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire five years from the date of issuance....
|
|
|
10.03.26 - 19:39
|
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering (GlobeNewswire EN)
|
|
|
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale in a registered direct offering of 4,500,785 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 4,500,785 shares of Common Stock at a combined offering price of $1.739 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant. The Accompanying Warrants will have an exercise price of $1.614 per share of Common Stock, will be exercisable at any time after the date of issuance, subject to certain ownership limitations, and will expire five years from the date of iss...
|
|
|
|
|
23.02.26 - 09:51
|
XFRA: MWBMU - HANDELSUNTERBRECHUNG - TEIL 4 (XETRA)
|
|
|
CA57808L3056
JP3801600002
GG00BMB5XZ39
US05875B3042
GB00BL97B504
CA92540L1076
CA04271V1058
GB00BN7JZR28
AU0000157075
PLAQUA000014
GB0001646941
CA31866G1028
KYG8116R1074
CA64082X2032
IT0005439861
JP3756200006
IT0005433765
PLDTLGM00019
PLCCTLS00017
SE0013382066
PLCNSLB00012
BE0974374069
US5632457033
KYG9482E1180
US04681Y1038
PLSNKTK00019
CNE100006M66
CA42804X3058
US3131488682
US3131488435
SE0000395428
FI4000592159
CA02255Q2099
IT0005531238
CA37895W1095
CA0029471095
AU0000284895
SGXE32143393
JP3049110004
SGXE32247038
US29081P2048
US0126532003
US00654J2069
CA0213618865
SE0009242175
AU000000ASX7
CNE1000001Y8
MHY3130D1013
GB00B95L0551
KYG9560F1028
KYG464401143
US6294442099
CA38154G1081
KYG4914A1076
CNE100007F98
US94858P2092
KYG1331C1042
US05969A1051
GRS001003052
US0970232049
US09260U1097
ARP125991090
US0773472016
AU0000153215
CNE100000551
SE0015961594
CNE100000254
US0905721082
IT0005468357
US09075P2048
GRS246003008
NZCENE0001S6
US05070F3082...
|
|
|
|
|
|
|
|
|
|
|
13.10.25 - 13:03
|
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation (GlobeNewswire EN)
|
|
|
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO Vimal Mehta, Ph.D., and members of the BioXcel team will ring the Nasdaq Stock Market Closing Bell on Tuesday, October 14, 2025. This honor marks a pivotal moment for the company — celebrating BioXcel's breakthrough progress in addressing one of the most urgent unmet needs in psychiatry: the treatment of agitation associated with bipolar disorders and schizophrenia....
|
|
|
|
|
18.09.25 - 13:03
|
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements (GlobeNewswire EN)
|
|
|
NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the market value of listed securities (“MVLS”) requirement under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”)....
|
|
|
|
|
|
|
|
|
|
|
27.08.25 - 13:48
|
XFRA: BX20: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
BIOXCEL THERAP.INC.NEW BX20 US09075P2048
AB/FROM ONWARDS 27.08.2025 13:42 CET...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
